|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM193805235 |
| 003 |
DE-627 |
| 005 |
20231223195439.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2009.11.012
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0646.xml
|
| 035 |
|
|
|a (DE-627)NLM193805235
|
| 035 |
|
|
|a (NLM)20015694
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Hirohata, Shunsei
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Suppressive influences of IFN-alpha on IL-17 expression in human CD4+ T cells
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.03.2010
|
| 500 |
|
|
|a Date Revised 17.02.2010
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a 2009 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a We examined the direct effects of IFN-alpha on the development of Th17 with a system using immobilized anti-CD3, which permits activation of CD4+ T cells in the complete absence of accessory cells. Highly purified CD4+ T cells obtained from healthy donors were stimulated with immobilized anti-CD3 with or without IFN-alpha. IFN-alpha suppressed the production of IL-17 of immobilized anti-CD3-stimulated CD4+ T cells in a dose-response manner. Accordingly, IFN-alpha inhibited IL-17 mRNA expression in immobilized anti-CD3-stimulated CD4+ T cells. IFN-alpha did not affect the production of TGF-beta or IL-6, but inhibited RORC mRNA expression of anti-CD3-stimulated CD4+ T cells. These results indicate that IFN-alpha suppresses IL-17 expression and Th17 differentiation through down-regulation of RORC mRNA expression. It is therefore suggested that these effects might play a role in the mode of action of IFN-alpha in the treatment of various inflammatory diseases
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Interferon-alpha
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-17
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-6
|2 NLM
|
| 650 |
|
7 |
|a Nuclear Receptor Subfamily 1, Group F, Member 3
|2 NLM
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 650 |
|
7 |
|a RORC protein, human
|2 NLM
|
| 650 |
|
7 |
|a Transforming Growth Factor beta
|2 NLM
|
| 700 |
1 |
|
|a Shibuya, Hideki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tejima, Satoko
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 134(2010), 3 vom: 12. März, Seite 340-4
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:134
|g year:2010
|g number:3
|g day:12
|g month:03
|g pages:340-4
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2009.11.012
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 134
|j 2010
|e 3
|b 12
|c 03
|h 340-4
|